Non-alcoholic fatty liver disease affects 90 million Americans. It can lead to permanent liver dysfunction and even death. Although there are a number of clinical trials related to the disease, there are no pharmaceuticals approved for treatment. Organic Research Corp. is developing pathology software that will impact the efficiency of detecting NAFLD, called the Digital Liver Pathology Aid. The company presented to potential investors and others Nov. 12 during the Wisconsin Early Stage Symposium in Madison. Read the full WisBusiness story here.